About Antios Therapeutics
Antios Therapeutics is a company based in Atlanta (United States) founded in 2018 by Abel De La Rosa and Idean Marvasty. It operates as a HealthTech. Antios Therapeutics has raised $200.4 million across 4 funding rounds from investors including EPIQ, RA Capital and GordonMD Global Investments. Antios Therapeutics offers products and services including ATI-2173 and 4th Generation CAM Program. Antios Therapeutics operates in a competitive market with competitors including SSI Strategy, Fusion Antibodies, Health Decisions, August Research and Phastar, among others.
- Headquarter Atlanta, United States
- Founders Abel De La Rosa, Idean Marvasty
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Antios Therapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$200.4 M (USD)
in 4 rounds
-
Latest Funding Round
$75 M (USD), Series B
Nov 03, 2021
-
Investors
EPIQ
& 21 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Antios Therapeutics
Antios Therapeutics offers a comprehensive portfolio of products and services, including ATI-2173 and 4th Generation CAM Program. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
ATI-2173 is developed as HBV polymerase inhibitor nucleotide.
CAM program is designed for targeted HBV virus clearance.
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Antios Therapeutics
Antios Therapeutics has successfully raised a total of $200.4M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $75 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series B — $75.0M
-
First Round
First Round
(27 Nov 2018)
- Investors Count 22
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2021 | Amount | Series B - Antios Therapeutics | Valuation | GordonMD Global Investments , EPIQ | |
| Apr, 2021 | Amount | Series B - Antios Therapeutics | Valuation | Soleus Capital | |
| Aug, 2020 | Amount | Series A - Antios Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Antios Therapeutics
Antios Therapeutics has secured backing from 22 investors, including venture fund and institutional investors. Prominent investors backing the company include EPIQ, RA Capital and GordonMD Global Investments. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment management services are provided in the biopharmaceutical sector.
|
Founded Year | Domain | Location | |
|
Diversified asset management services are offered by EPIQ.
|
Founded Year | Domain | Location | |
|
Private equity investments are directed toward the healthcare sector.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Antios Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Antios Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Antios Therapeutics Comparisons
Competitors of Antios Therapeutics
Antios Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as SSI Strategy, Fusion Antibodies, Health Decisions, August Research and Phastar, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Pharmacovigilance and medical affairs services are offered for drug development.
|
|
| domain | founded_year | HQ Location |
Company offering a range of services in antibody production, development, characterization and optimization right from discovery to commercialization
|
|
| domain | founded_year | HQ Location |
CRO focused on clinical trial services for data management, monitoring and biostatistics
|
|
| domain | founded_year | HQ Location |
Clinical trial services are offered in Central and Eastern Europe.
|
|
| domain | founded_year | HQ Location |
Statistical consulting and data management for clinical trials are offered.
|
|
| domain | founded_year | HQ Location |
Regulatory and pharmacovigilance support is provided for product lifecycles.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Antios Therapeutics
Frequently Asked Questions about Antios Therapeutics
When was Antios Therapeutics founded?
Antios Therapeutics was founded in 2018.
Where is Antios Therapeutics located?
Antios Therapeutics is headquartered in Atlanta, United States. It is registered at Atlanta, Georgia, United States.
Who is the current CEO of Antios Therapeutics?
Abel De La Rosa is the current CEO of Antios Therapeutics. They have also founded this company.
Is Antios Therapeutics a funded company?
Antios Therapeutics is a funded company, having raised a total of $200.4M across 4 funding rounds to date. The company's 1st funding round was a Series A of $4.4M, raised on Nov 27, 2018.
What does Antios Therapeutics do?
Antios Therapeutics is engaged in the development of innovative therapies aimed at treating and potentially curing hepatitis B virus (HBV) and other viral diseases. The company is known for developing ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), which is combined with nucleoside analogues to inhibit HBV replication. Additionally, a 4th generation capsid assembly modulator (CAM) program is being advanced to support immune system clearance of HBV. Their work spans clinical trials and research presentations, contributing to advancements in antiviral treatments within the healthcare sector.
Who are the top competitors of Antios Therapeutics?
Antios Therapeutics's top competitors include SSI Strategy, Fusion Antibodies and ProductLife Group.
What products or services does Antios Therapeutics offer?
Antios Therapeutics offers ATI-2173 and 4th Generation CAM Program.
Who are Antios Therapeutics's investors?
Antios Therapeutics has 22 investors. Key investors include EPIQ, RA Capital, GordonMD Global Investments, CAM Capital, and Avego.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.